Nob Hill Therapeutics, an Albuquerque, NM-based an early-stage pulmonary medical device and therapeutics company, raised $3M in Series A funding.
The round was led by Tramway Venture Partners and included investments from TCA Venture Group and VIC Technology Venture Development (which founded NHT). In connection with the financing, Chris Japp, Managing Partner of Tramway Venture Partners, will join Nob Hill’s Board of Directors. Sima Ghafari of TCA Venture Group will join as a Board Observer.
The company intends to use the funds for the continued development of its high-dose respiratory technology and therapeutics, including pre-IND studies.
Led by CEO Noel Greenberger, Nob Hill Therapeutics is a respiratory-focused healthcare company that uses high dose lung delivery to treat lung-related diseases. Its patented Dry Powder Nebulizer platform has several technological innovations that enable it to generate drug aerosols and deliver them effectively to the lower respiratory tract, independent of the patient’s lung capacity.
NHT has a patent-protected inhalation device technology capable of delivering high therapeutic doses directly to the lung. It is suitable for patients of all ages and inhalation capabilities, including patients with compromised lung function.
FinSMEs
06/08/2024